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Abstract
Recent studies show that patients with myotonic dystrophy (DM) have an increased risk of specific malignancies, but
estimates of absolute cancer risk accounting for competing events are lacking. Using the Swedish Patient Registry,
we identified 1,081 patients with an inpatient and/or outpatient diagnosis of DM between 1987 and 2007. Date and
cause of death and date of cancer diagnosis were extracted from the Swedish Cause of Death and Cancer
Registries. We calculated non-parametric estimates of absolute cancer risk and cancer mortality accounting for the
high non-cancer competing mortality associated with DM. Absolute cancer risk after DM diagnosis was 1.6% (95%
CI=0.4-4%), 5% (95% CI=3-9%) and 9% (95% CI=6-13%) at ages 40, 50 and 60 years, respectively. Females had a
higher absolute risk of all cancers combined than males: 9% (95% CI=4-14), and 13% (95% CI=9-20) vs. 2%
(95%CI= 0.7-6) and 4% (95%CI=2-8) by ages 50 and 60 years, respectively) and developed cancer at younger ages
(median age =51 years, range=22-74 vs. 57, range=43-84, respectively, p=0.02). Cancer deaths accounted for 10%
of all deaths, with an absolute cancer mortality risk of 2% (95%CI=1-4.5%), 4% (95%CI=2-6%), and 6%
(95%CI=4-9%) by ages 50, 60, and 70 years, respectively. No gender difference in cancer-specific mortality was
observed (p=0.6). In conclusion, cancer significantly contributes to morbidity and mortality in DM patients, even after
accounting for high competing DM mortality from non-neoplastic causes. It is important to apply population-
appropriate, validated cancer screening strategies in DM patients.
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Introduction
Myotonic Dystrophy (DM) is the most common adult muscle
dystrophy. It is a chronic, slowly-progressive, autosomal
dominant, multisystem disorder. Two major DM types have
been identified: type 1 (DM1), caused by a CTG repeat
expansion in the 3’ untranslated region of the dystrophia
myotonica-protein kinase (DMPK) gene (chromosome 19q13.2)
[1–3], and type 2 (DM2), caused by a CCTG repeat expansion
in intron 1 of the zinc finger 9 (ZNF9) gene (chromosome 3q21)
[4,5]. In addition to progressive skeletal muscle weakness and
myotonia, DM patients may suffer from cardiac conduction
defects, insulin-resistance, testicular atrophy, and respiratory
insufficiency [6]. The complex clinical phenotype of this disease
has been attributed to dysregulation in the pre-mRNA splicing
process of multiple genes [4,7–9].
Several prior studies have suggested a high risk of
premature death in DM patients (mean age at death: early 50s)
[10–13]. The main reported causes of death were respiratory
and cardiac complications, followed by malignancy.
Nonetheless, until recently, DM patients were not formally
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considered to be at a clinically significant increased risk of
cancer.
Using the Swedish and Danish population-based registries,
we previously reported that patients with DM (n=1,658) were at
high risk of cancers of the brain, colon, endometrium, ovary,
and possibly cancers of the eye, thyroid gland, and non-
melanoma skin [14]. The excess risks of thyroid and eye
cancers have been replicated in a subsequent clinic-based
study of 307 DM cases [15]. While the comparison of risk
among DM patients in relation to the general population
provides etiological insights, the absolute risk estimates (also
called cumulative incidence) are more useful for the clinical
management of individual patients.
Therefore, in the current study, we used the Swedish
population-based registries to provide a comprehensive
assessment of the absolute risk of cancer incidence and
cancer mortality after DM diagnosis, while statistically
accounting for the high competing risks from non-cancer
deaths among patients with this disorder.
Subjects and Methods
Swedish Population Registries and Study Participants
From the Swedish Patient Registry, we identified all
individuals with a DM discharge diagnosis (the International
Classification of Diseases (ICD) 9th version=359C or
ICD-10=G711) between January 1, 1987 and December 31,
2007 (n=1,121). The Swedish Patient Registry began in 1964
and reached 100% coverage of nationwide hospitalizations in
1987. Outpatient data were added starting in 2000. All Registry
diagnoses were coded according to either ICD-9: 1987-1995,
or ICD-10, thereafter [16,17].
Using each individual’s national identification number, DM
patients were linked to the Swedish Cause of Death Registry to
obtain date and cause of death. Forty DM subjects were
excluded because they died during their first DM
hospitalization. The remaining 1,081 DM patients were linked
to the Swedish Cancer Registry to ascertain cancer diagnosis.
The Swedish Cancer registry has collected detailed information
on incident cancer cases throughout Sweden since 1958. All
cancer diagnoses were coded according to the ICD-7 through
ICD-10. The completeness and diagnostic accuracy of the
cancer registry exceeded 95% in validation studies [18,19].
When calculating absolute risk of cancer after a DM diagnosis,
we included only DM patients who had not been diagnosed
with cancer prior to the date of first DM diagnosis (n=1,015).
Only first primary cancers were included in this analysis. Death
and cancer data were available through December 31, 2007.
Figure 1 summarizes patient selection for this study.
Ethics Statement
The study was performed in accordance with the ethical
standards laid down in the 1964 Declaration of Helsinki. The
requirement for informed consent was waived because we had
neither direct contact with, nor personal identifying information
from, study subjects. An exemption from the National Institute
of Health (NIH) Institutional Review Board review was obtained
from the National Institutes of Health Office of Human Subjects
Research because we used existing data without personal
identifiers.
Statistical Analysis
For all primary analyses, follow-up started at age of first DM
discharge diagnosis if first diagnosed after 1987, or age in
January 1st 1987 otherwise. Patient age was used as the time
metric, and late entry into the study was accounted for in all
computations.
To describe survival patterns in patients with DM, we
calculated the probability of survival and 95% confidence
intervals (CI) using the Kaplan-Meier estimator. A log-rank test
was used to compare the survival distributions between
categories.
We estimated the absolute risk of cancer mortality and
cancer incidence in DM patients after their first DM diagnosis,
accounting for the competing risk caused by non-cancer deaths
non-parametrically using (STATA stcompet). We also
investigated risk and mortality of cancers stratified by gender.
Standard errors were computed as described in Marubini &
Valsecchi [20].
In a secondary analysis, we calculated lifetime risk of
developing cancer based on all DM patients (n=1,081). Follow-
up started at birth (if born subsequent to January 1, 1958), or at
the start of the cancer registry (January 1st 1958) otherwise.
Follow-up ended at age of the event of interest (cancer death
for cancer mortality analyses, and age at first primary cancer
diagnosis for cancer absolute risk analyses), age at death from
non-cancer causes, or age at censoring. Censoring events
were emigration or end of study (December 31, 2007). All
analyses were performed using STATA12 (StataCorp, College
Station, TX, USA)
Results
The study included 1,081 DM patients who were followed for
up to 21 years, contributing 7,735 person-years of follow-up.
Approximately half (47.9%) of the patients were male. The
median age at DM diagnosis was 46 years (range=0-86),
38.9% of subjects died during follow-up, and 11.5% (n=124)
developed cancer (Table S1 shows cancers by anatomic site
diagnosed before and after first DM discharge diagnosis)
Similar distributions of gender, and age at DM diagnosis were
observed when comparing DM patients by source of diagnosis
(inpatient vs. outpatient). However, more deaths and more
cancers occurred in those diagnosed as inpatients, possibly
indicating that those hospitalized manifested more severe
underlying disease phenotype (Table 1).
Absolute Risk of Cancer after DM Diagnosis
Among the 1,015 patients without a prior cancer diagnosis at
the beginning of follow-up (contributing 7,297 person-years of
follow-up), 58 patients developed incident cancers at a median
age of 54 years (range=22-84). Female patients developed
cancer at a younger age than males (median age=51 years,
range=22-74 vs. 57, range=43-84, respectively; p=0.02).
Cancers of the breast (n=9), endometrium (n=6), and ovary
Cancer Burden in Myotonic Dystrophy
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Figure 1.  Flow chart describing the selection of study participants from the Swedish Patient Registry.  
doi: 10.1371/journal.pone.0079851.g001
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(n=5) were the most frequent neoplasms in women, while lung
cancer was the most frequent in men (n=5).
Overall, the absolute risk of cancer after DM diagnosis
increased from 1.6% (95%CI=0.4-4.3%), to 5.1% (95%
CI=2.8-8.6%) and 8.8% (95% CI=5.7-12.7%) by ages 40, 50
and 60 years, respectively. In analyses stratified by gender, the
absolute risk of all cancers combined was significantly higher in
females than males (p=0.03): 7.8% (95% CI=3.7-13.9%) and
13.3% (95% CI=7.8-20.2%) versus 2.3% (95%CI= 0.7-5.8%)
and 4.4% (95%CI=2.0-8.2%) by ages 50 and 60 years,
respectively.
In analyses restricted to female patients, absolute risk of
reproductive cancers (endometrium, cervix, ovary, and other
female genital organs) was 1.0 % (95%CI=0.09-5.0%), 3.4%
(95%CI=1.1-7.9%) and 4.6% (95%CI=1.9-9.4%) compared with
risks of non-reproductive cancers (including breast) that were
2% (95%CI=0.4-6%), 4.5% (95%CI=1.7-9.3%), and 9%
(95%CI=4.7-14.1%) by ages 40, 50, and 60 years, respectively.
When we evaluated lifetime absolute risk of cancer in all DM
patients (i.e., including cancers diagnosed before the first DM
diagnosis), estimates were higher, particularly at younger age,
than those based on cancers diagnosed after DM diagnosis
(0.2% [95% CI=0.02-0.1%] by age 20; 2.6% [95% CI=1.7-3.9%]
by age 40; 5.8% [95% CI=4.3-7.6%] by age 50, and 12% [95%
CI=9.7-14.6%] by age 60 years). These results however, have
to be interpreted with caution because of potential biases
relating to DM under-diagnosis or under-reporting.
Table 1. Characteristics of all myotonic dystrophy patients
and by source of first diagnosis.
Variable
All Patients
(N=1081)
Inpatient
Diagnosis
(N=718)
Outpatient
Diagnosis (N=363)
N (%)
Gender
Male 518 (47.9) 339 (47.2) 179 (49.3)
Female 563 (52.1) 379 (52.8) 184 (50.7)
Age at DM diagnosis (Yrs)
Median (range) 46 (0-86) 46.0 (0-86) 44.0 (1-80)
0-33 298 (26.3) 198 (25.9) 100 (27.3)
34-47 305 (26.9) 202 (26.4) 103 (28.1)
48-57 276 (24.4) 183 (23.9) 93 (25.3)
57+ 253 (22.4) 182 (23.8) 71 (19.4)
Calendar year at first DM diagnosis
1987-1993 388 (34.3) 388 (50.7) 0
1994-1999 232 (20.5) 232 (30.3) 0
2000-2003 329 (29.1) 101 (13.2) 228 (62.1)
2003-2007 183 (16.2) 44 (5.8) 139 (37.9)
Developed cancer
evera 124 (11.5) 99 (13.8) 25 (6.9)
Age at
diagnosis(Yrs);
Median (range)
51 (2-84) 51.5 (2-84) 51 (22-76)
a. Either before or after the beginning of prospective follow-up.
doi: 10.1371/journal.pone.0079851.t001
Survival Patterns and Absolute Risk of Cancer Mortality
after DM Diagnosis
The median age of death among all DM patients was 49.8
years (95% CI=39.8-53.8). DM itself was the most common
registered primary cause of death (n=232; 55.1%), followed by
cardiovascular disease (n=95; 22.6%; mainly ischemic heart
disease, n=39), malignancy (n=42; 10.0%; cancers of the ovary
(n=8), brain (n=7), and lung (n=6) were the most common), and
respiratory disease (n=13; 3.1%; mainly infections, n=10).
Among those for whom DM was the primary cause of death,
the most commonly reported secondary causes were:
respiratory (n=80, 12 of whom died of respiratory failure),
followed by cardiac causes (n=17). The first death among study
participants occurred at age 4 months; the first cancer death
occurred at age 41 years.
The absolute risks of cancer mortality after DM diagnosis in
all patients increased from 2.3% (95% CI=1.0-4.5%) to 3.9%
(95% CI=2.1-6.4%), and 5.9% (95% CI=3.7-8.7%) by ages 50,
60, and 70 years compared with 48.1% (95% CI=35.8-59.3%),
72.7% (95% CI=65.0-78.9%), and 88.6% (95%CI=84.5-91.7%)
for non-cancer deaths by the same ages respectively.
In analyses stratified by gender, male patients had poorer
survival overall (63% [95% CI=40-80%]; 45% [95%
CI=29-59%]; and 17% [95% CI=12-25%] vs. females 70%
[95% CI=46-84%]; 55% [95% CI=38-69%]; and 31% [95%
CI=21-41%] by ages 40, 50 and 60 years, respectively; log-
rank p<0.0001). After accounting for the competing risk of non-
cancer deaths, a similar pattern was observed for cancer
mortality, particularly in younger patients, although this was not
statistically significant (p=0.6). In male patients, the absolute
risk of cancer mortality were 3.0% (95% CI=1.0-6.9%), 4.7%
(95% CI=2.1-8.8%), and 5.6% (95% CI=2.8-9.9%) vs. 1.4%
(95% CI=0.2-4.6%), 2.9% (95% CI=1.1-6.3%), and 6.3% (95%
CI=3.4-10.4%) in females by age 50, 60, and 70 years,
respectively. Figure 2 summarizes the absolute age-specific
risks of cancer incidence, cancer mortality, and other causes of
death among study participants, overall and by gender.
Discussion
We previously quantified the relative risk of cancer among
patients with myotonic dystrophy in comparison with the
general population [14]. Because of the possible clinical
implications of those novel observations, we now present the
absolute risk of cancer incidence and cancer mortality after DM
diagnosis, while statistically accounting for the high probability
of competing non-cancer mortality. Our findings can be used by
physicians to communicate cancer risk to their DM patients,
and provide a rationale for routinely applying validated,
population-appropriate cancer screening strategies to the
management of DM patients.
Our study is the first to account for the high competing risk
from non-cancer deaths in calculating cancer risk and mortality
for DM patients. In the presence of competing mortality, which
precludes the occurrence of other outcomes of interest (in this
instance, the development of new cancers), it is important to
employ a competing risk analysis to avoid overestimating the
magnitude of cancer risk [21].
Cancer Burden in Myotonic Dystrophy
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Figure 2.  Cumulative incidence curves summarizing
cancer burden in patients with myotonic dystrophy.  A)
Cumulative incidence curves for cancer incidence, cancer
mortality and other causes of death in all DM patients; B)
Cumulative incidence curves for cancer incidence, cancer
mortality and other causes of death in all DM patients in male
patients; C) Cumulative incidence curves for cancer incidence,
cancer mortality and other causes of death in all DM patients in
female patients.
doi: 10.1371/journal.pone.0079851.g002
Overall, absolute cancer risk after DM diagnosis increased
from 1.6% by age 40 years to 5% and 9% by ages 50 and 60
years, respectively. The observed gender difference in the risk
of all cancers combined was driven by the high incidence of
female cancers, including cancers of the breast and
reproductive organs. After excluding cancers of the genital
organs and the breast, the absolute risk of the remaining
cancers was not statistically different between males and
females (p=0.41). Compared with the general population,
female DM patients are at high risk of cancers of the
endometrium and ovary [14]. The high frequency of breast
cancer in female DM patients has been observed previously
[14,15,22] (in general, breast cancer is the most common
tumors in women) but breast cancer risk was comparable to
that of women from the general population [14,15]. Based on
that observation, we do not currently view breast cancer as part
of the DM phenotype; its presence in this series likely reflects
its relatively high incidence in the general population.
Of interest, and when compared with cancer cumulative
incidence of the general Swedish population, the absolute risk
of cancer in female (but not male) DM patients exceeded that
of the population of the same ages (in females: 14.6% vs. 7.7%
[23], in males 3.5% vs. 4.4% [23] by age 55). The higher death
rates among male DM patients versus females may contribute
to this observation (by 60 years of age, the overall survival
probability in male patients is 17% compared with 31% in
females).
Calculating the absolute risk of cancer after DM diagnosis
provides clinically useful estimates for physician-patient
communication purposes, and minimizes possible biases
expected if one used lifetime estimates for this purpose, since
there is no way to identify patients who died from cancer prior
to their being recognized as having DM.
In this large population-based study, and in agreement with
previous reports, DM patients were at very high risk of
premature death. Sweden has one of the highest life
expectancies in the world (mean life expectancy = 81.8 years in
2011) [24], while the median age of death for DM patients in
this study was 49.8 years, an estimate that is similar to prior
reports from the US [11] and the Netherlands [10].
Furthermore, several prior studies have suggested a survival
advantage for female DM patients [10,13], an observation that
was confirmed in our study overall. Cancer death was the third
most common cause of death among DM patients; an
observation that had been noted in passing in earlier
publications, but which did not attract clinical attention [10–13].
The under-recognition of the cancer mortality burden in DM
patients is possibly driven by the significant high competing
death attributed to non-cancer causes in those patients. After
accounting for the very high competing non-cancer mortality
(48%, 73%, and 89% by ages 50, 60, and 70 years), the
absolute risk of cancer death in DM patients reached 2%, 4%
and 6% by the same ages. While cancer is a distant third on
the list of DM-associated causes of death, it nonetheless
accounts for 10% of all deaths in DM patients, and it is quite
possible that a meaningful fraction of those deaths could be
avoided if cancer were consciously considered (by applying
validated, population-appropriate screening) in both the day-to-
Cancer Burden in Myotonic Dystrophy
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day health care of DM patients, and in the differential diagnosis
of new, unexplained medical signs or symptoms. Minimizing
diagnostic delay is a worthwhile goal in this context.
The strengths of our study include its population-based
design that minimizes selection bias, and the use of registry-
based records to verify diagnoses that minimizes recall bias.
The study included DM patients identified from both inpatient
and outpatient records, improving the external validity and
generalizability of our results. The study limitations include the
lack of information on known cancer risk factors, genetic
subtype of DM disease in affected individuals (i.e., DM1 versus
DM2), nucleotide repeat length which, at least for DM1, is
thought to correlate strongly with disease severity. Previous
research [22,25] suggested that there is no association
between nucleotide repeat expansion size and cancer risk in
DM patients; additional research is needed in this area. It is
likely that there are more DM1 cases among patients in the
current series since it is both more prevalent in the general
population, and it was also characterized genetically before
DM2. Due to the small observed numbers of individual site-
specific cancers, we were not able to calculate reliable site-
specific cancer absolute risks or mortality estimates. Finally,
the Swedish database did not contain DM-specific clinical
information such as disease severity.
In conclusion, our study provides the first quantification of
cancer burden after DM diagnosis, accounting for the high non-
cancer competing mortality associated with this multisystem
disease. Importantly, cancer remains a meaningful contributor
to DM-related morbidity and, to a lesser extent, mortality. The
molecular mechanism underlying the increased cancer risk in
DM patients remains to be defined, but several mechanisms
have been hypothesized [14,26]. Future research is needed to
understand the mechanisms of DM-associated carcinogenesis
and to clarify whether nucleotide repeat expansion size is a
modifier of this relationship. It is important to incorporate
validated population-based cancer screening modalities into
the routine clinical care of DM patients, and to evaluate
suspicious new symptoms with the possibility of cancer in
mind. Early onset active surveillance through detailed medical
history and careful physical examination with an eye towards
minimizing diagnostic delay is important relative to cancers for
which screening has not been proven beneficial, such as
ovarian, endometrial and brain cancers. Reevaluation of cancer
incidence in DM patients will be necessary as more effective
DM treatments are developed, since cancer incidence and its
associated mortality burden, are likely to increase as
competing risks diminish.
Supporting Information
Table S1.  Cancer sites before and after start of follow-up.
(DOCX)
Acknowledgements
The authors thank Ms. Shiva Ayoubi, the National Board of
Health and Welfare, Stockholm, Sweden, Ms. Emily Steplowski
and Mr. Joseph Barker, Information Management Services,
Silver Spring, MD, for important contributions to the
development of this database.
Author Contributions
Conceived and designed the experiments: SMG RMP MHG.
Performed the experiments: SMG. Analyzed the data: SMG
RMP. Contributed reagents/materials/analysis tools: SYK MB
RMP OL. Wrote the manuscript: SMG MHG RMP SYK MB JEH
RTM OL.
References
1. Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D et al.
(1992) Molecular basis of myotonic dystrophy: expansion of a
trinucleotide (CTG) repeat at the 3' end of a transcript encoding a
protein kinase family member. Cell 69: 385. doi:
10.1016/0092-8674(92)90440-N. PubMed: 15682521310900.
2. Fu YH, Pizzuti A, Fenwick RG Jr., King J, Rajnarayan S et al. (1992)
An unstable triplet repeat in a gene related to myotonic muscular
dystrophy. Science 255: 1256-1258. doi:10.1126/science.1546326.
PubMed: 1546326.
3. Mahadevan M, Tsilfidis C, Sabourin L, Shutler G, Amemiya C et al.
(1992) Myotonic dystrophy mutation: an unstable CTG repeat in the 3'
untranslated region of the gene. Science 255: 1253-1255. doi:10.1126/
science.1546325. PubMed: 1546325.
4. Ranum LP, Day JW (2002) Myotonic dystrophy: clinical and molecular
parallels between myotonic dystrophy type 1 and type 2. Curr Neurol
Neurosci Rep 2: 465-470. doi:10.1007/s11910-002-0074-6. PubMed:
12169228.
5. Liquori CL, Ricker K, Moseley ML, Jacobsen JF, Kress W et al. (2001)
Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of
ZNF9. Science 293: 864-867. doi:10.1126/science.1062125. PubMed:
11486088.
6. Harper PS (2001) Myotonic dystrophy. Philadelphia: WB Saunders.
7. Du H, Cline MS, Osborne RJ, Tuttle DL, Clark TA et al. (2010) Aberrant
alternative splicing and extracellular matrix gene expression in mouse
models of myotonic dystrophy. Nat Struct Mol Biol 17: 187-193. doi:
10.1038/nsmb.1720. PubMed: 20098426. nsmb.1720
8. Osborne RJ, Lin X, Welle S, Sobczak K, O'Rourke JR et al. (2009)
Transcriptional and post-transcriptional impact of toxic RNA in myotonic
dystrophy. Hum Mol Genet 18: 1471-79. doi:10.1093/hmg/ddp058.
PubMed: 19223393.
9. Vihola A, Bachinski LL, Sirito M, Olufemi SE, Hajibashi S et al. (2010)
Differences in aberrant expression and splicing of sarcomeric proteins
in the myotonic dystrophies DM1 and DM2. Acta Neuropathol, 119:
20066428.
10. de Die-Smulders CE, Höweler CJ, Thijs C, Mirandolle JF, Anten HB et
al. (1998) Age and causes of death in adult-onset myotonic dystrophy.
Brain 121 ( 8): 1557-1563. doi:10.1093/brain/121.8.1557. PubMed:
9712016.
11. Groh WJ, Groh MR, Shen C, Monckton DG, Bodkin CL et al. (2011)
Survival and CTG repeat expansion in adults with myotonic dystrophy
type 1. Muscle Nerve 43: 648-651. doi:10.1002/mus.21934. PubMed:
21484823.
12. Mathieu J, Allard P, Potvin L, Prévost C, Bégin P (1999) A 10-year
study of mortality in a cohort of patients with myotonic dystrophy.
Neurology 52: 1658-1662. doi:10.1212/WNL.52.8.1658. PubMed:
10331695.
13. Mladenovic J, Pekmezovic T, Todorovic S, Rakocevic-Stojanovic V,
Savic D, Romac S et al. (2006) Survival and mortality of myotonic
dystrophy type 1 (Steinert's disease) in the population of Belgrade. Eur
J Neurol 13: 451-454. doi:10.1111/j.1468-1331.2006.01261.x. PubMed:
16722967.
14. Gadalla SM, Lund M, Pfeiffer RM, Gørtz S, Mueller CM et al. (2011)
Cancer risk among patients with myotonic muscular dystrophy. JAMA
306: 2480-2486. doi:10.1001/jama.2011.1796. PubMed: 22166607.
15. Win AK, Perattur PG, Pulido JS, Pulido CM, Lindor NM (2012)
Increased Cancer Risks in Myotonic Dystrophy. Mayo Clin Proc, 87:
S0025-S6196. PubMed: 22237010. doi:10.1016/j.mayocp.2011.09.005
Cancer Burden in Myotonic Dystrophy
PLOS ONE | www.plosone.org 6 November 2013 | Volume 8 | Issue 11 | e79851
16. (1998) Patientregistret 1987-1996: Kvalitet och innehåll (Swedish).
17. Nilsson AC, Spetz CL, Carsjo K, Nightingale R, Smedby A (1994)
Slutenvardsregistrets tillforlitlighet. Diagnosuppgifterna battre an sitt
rykte. (The reliability of the Hospital Discharge Register. the discharge
diagnoses are more correct than the common belief). Lakartidningen
91: 598-605..
18. Mattsson B, Wallgren A (1984) Completeness of the Swedish Cancer
Register. Non-notified cancer cases recorded on death certificates in
1978. Acta Radiol Oncol 23: 305-313. doi:
10.3109/02841868409136026. PubMed: 6095600.
19. Turesson I, Linet MS, Björkholm M, Kristinsson SY, Goldin LR et al.
(2007) Ascertainment and diagnostic accuracy for hematopoietic
lymphoproliferative malignancies in Sweden 1964-2003. Int J Cancer
121: 2260-2266. doi:10.1002/ijc.22912. PubMed: 17583571.
20. Marubini E, Valsecchi MG (1995) Analysing Survival Data from Clinical
Trials and Observational Studies. John Wiley & Sons Ltd.
21. Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach
AD (2004) A note on competing risks in survival data analysis. Br J
Cancer 91: 1229-1235. doi:10.1038/sj.bjc.6602102. PubMed:
15305188.
22. Das M, Moxley RT III, Hilbert JE, Martens WB, Letren L et al. (2012)
Correlates of tumor development in patients with myotonic dystrophy. J
Neurol, 259: 2161–6. doi:10.1007/s00415-012-6476-8. PubMed:
22619053.
23. The National Board of Health and Welfare (2008) Cancer Incidence in
Sweden 2007. Available: http://www.socialstyrelsen.se/lists/
artikelkatalog/attachments/8715/2008-125-16_200812516_rev2.pdf.
Accessed: 28 July 2013.
24. Organisation for Economic Co-operation and Development (OECD)
Health Data 2011 (2012) Life expectancy at birth, total population.
Available: http://www.oecd-ilibrary.org/social-issues-migration-health/
life-expectancy-at-birth-total-population-2012-1_lifexpy-total-
table-2012-1-en. Accessed: 15 January 2013.
25. Mohamed S, Pruna L, Kaminsky P (2013) Increasing risk of tumors in
myotonic dystrophy type 1. Presse Med: S0755-S4982. doi:10.1016/
j.lpm.2013.01.052.
26. Mueller CM, Hilbert JE, Martens W, Thornton CA, Moxley RT III et al.
(2009) Hypothesis: neoplasms in myotonic dystrophy. Cancer Causes
Control
Cancer Burden in Myotonic Dystrophy
PLOS ONE | www.plosone.org 7 November 2013 | Volume 8 | Issue 11 | e79851
